Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties

James A. McCubrey; Akshaya K. Meher; Shaw M. Akula; Stephen L. Abrams; Linda S. Steelman; Michelle M. LaHair; Richard A. Franklin; Alberto M. Martelli; Stefano Ratti; Lucio Cocco; Fulvio Barbaro; Przemys&#x142;aw Duda; Agnieszka Gizak

doi:doi:10.18632/aging.204038

← Back

Research Paper Volume 14, Issue 8 pp 3365—3386

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties

Figure 11. Effects of pLXSN and WT-TP53 on the colony formation in soft agar in the presence of docetaxel. The effects of pLXSN and WT-TP53 on the colony formation in soft agar in MIA-PaCa-2 and PANC-28 cells were examined. (A) MIA-PaCa-2 + pLXSN (red bars) and MIA-PaCa-2 + WT-TP53 (blue bars) were compared in response to docetaxel. (B) PANC-28 + pLXSN (red bars) and PANC-28 + WT-TP53 (blue bars) were compared in response to docetaxel. The colonies for each cell line were normalized to untreated so that the results from pLXSN and WT-TP53 could be compared. These studies were repeated and similar results were observed. ^***P < 0.0001, ^**P < 0.005 and ^*P < 0.05, NS = not statistically significant.